Taro announces FDA approvals
-
- September
- 21
Taro Pharmaceutical Industries Ltd., a generic drug company based in Hawthorne, said that it has received approvals from the U.S. Food and Drug Administration on a drug application for Ciclopirox nail lacquer that is used for the topical treatment of onychomycosis, a fungal infection of the fingernails and toenails.
The FDA also approved Taro’s drug application for Loratadine syrup, an over-the-counter medication used for the relief of symptoms caused by the seasonal allergic rhinitis.
In May, Taro agreed to be bought by Sun Pharmaceutical Industries Ltd. of Mumbai, India, for $454 million.
This entry was posted
on Friday, September 21st, 2007 at 12:21 pm by Jay Loomis.
You can follow any responses to this entry through the RSS 2.0 feed.
Print
| 
Email
